GATC Health’s Post

GATC Health is discovering new treatments for opioid use disorder. At the 2026 NDASA Conference, our Chief Business Officer, V. Tyrone Lam was invited onstage by Stephen Loyd, MD, West Virginia's Director of Drug Policy and one of the most respected voices in addiction medicine in the country, to discuss GATC Health’s potential breakthrough in the support of those suffering from opioid use disorder. GATC-1021, GATC Health’s drug candidate as a potential treatment for opioid use disorder, was identified using GATC Health’s Operon™ AI platform to more precisely target the specific neurological dysregulations found in individuals with Opioid Use Disorder (OUD). PNAS: https://lnkd.in/gYfxz6n8 Fierce Biotech: https://lnkd.in/gnAdFeGG Drug Discovery News: https://lnkd.in/ggiir_Tz GATC Health Operon™ Platform: https://lnkd.in/gJ8BXZdX #GATCHealth #Operon #Derisq #DrugDiscovery #OpioidUseDisorder WVU Innovation Corporation